| Endostatin? VEGF-C和VEGFR-3在非小细胞肺癌及其淋巴结组织中的表达与意义 |
| |
| 引用本文： | 李少雷,陈晋峰,郑庆锋,吴楠,阎石,王洋,张建芝,杨跃. Endostatin? VEGF-C和VEGFR-3在非小细胞肺癌及其淋巴结组织中的表达与意义[J]. 中国肿瘤临床, 2011, 38(24): 1519-1523. DOI: 10.3969/j.issn.1000-8179.2011.24.010 |
| |
| 作者姓名： | 李少雷 陈晋峰 郑庆锋 吴楠 阎石 王洋 张建芝 杨跃 |
| |
| 作者单位： | 北京大学临床肿瘤学院胸外二科,北京肿瘤医院暨北京市肿瘤防治研究所,恶性肿瘤发病机制及转化研究教育部重点实验室 (北京市100142) |
| |
| 摘 要： | 探讨内皮抑素（endostatin）、血管内皮生长因子-C（VEGF-C）和血管内皮生长因子受体-3（VEGFR-3）在癌组织及其淋巴结组织中的表达与非小细胞肺癌（NSCLC）生物学行为之间的关系，了解endostatin、VEGF-C和VEGFR-3三者之间的内在联系。方法:使用免疫组化链霉菌抗生物素蛋白-过氧化物酶（SP）连接法对98例肺癌根治手术后癌组织和淋巴结组织标本的endostatin、VEGF-C和VEGFR-3的表达情况进行研究。结果:endostatin、VEGF-C、VEGFR-3在癌组织中的阳性表达率分别为30.6%、79.6%、61.2%。其中endostatin的表达与VEGF-C的表达呈正相关（P=0.025），VEGF-C的表达与VEGFR-3的表达呈正相关（P=0.007）。不同N分期及不同淋巴结转移枚数分组的患者，其endostatin和VEGF-C的阳性表达率均有显著性差异（P<0.05），且两者之间的变化呈相反趋势。VEGFR-3的表达与分化程度相关（P=0.013）。VEGF-C的表达情况与脉管癌栓相关（P=0.050）。在转移性淋巴结中，VEGF-C和VEGFR-3的阳性表达率均达88.0%，未转移淋巴结中，两者的阳性表达率分别为32.7%和57.1%，差异有统计学意义（P<0.001）。转移性淋巴结中微淋巴管密度（MLVD）明显高于非转移淋巴结（P<0.001）。结论:endostatin和VEGF-C的表达与肺癌淋巴结转移密切相关，endostatin可能通过下调VEGF-C的表达来抑制淋巴结转移，VEGF-C/VEGFR-3通路通过促进微淋巴管的增生直接参与淋巴结转移，对寻找治疗肺癌的新途径有重要意义。
|
| 关 键 词： | 内皮抑素 血管内皮生长因子C 血管内皮生长因子受体3 非小细胞肺癌 淋巴结转移 |
| 收稿时间： | 2011-08-27 |
Expression and Clinical Evaluation of Endostatin,VEGF-C,and VEGFR-3 in Non-small Cell Lung Cancer and Lymph Node Tissues |
| |
| Shaolei LI,Jinfeng CHEN,Qingfeng ZHENG,Nan WU,Shi YAN,Yang WANG,Jianzhi ZHANG,Yue YANG. Expression and Clinical Evaluation of Endostatin,VEGF-C,and VEGFR-3 in Non-small Cell Lung Cancer and Lymph Node Tissues[J]. Chinese Journal of Clinical Oncology, 2011, 38(24): 1519-1523. DOI: 10.3969/j.issn.1000-8179.2011.24.010 |
| |
| Authors: | Shaolei LI Jinfeng CHEN Qingfeng ZHENG Nan WU Shi YAN Yang WANG Jianzhi ZHANG Yue YANG |
| |
| Affiliation: | Thoracic Surgery Ⅱ, Beijing Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University School of Oncology, Beijing 100142, China |
| |
| Abstract: | To investigate the expression of endostatin, vascular endothelial growth factor C ( VEGF-C ), and vascular endothelial growth receptor 3 ( VEGFR-3 ) in non-small lung cancer ( NSCLC ) and lymph node tissues, and to explore their clinical significance. Methods: The immunohistochemical streptavidin-perosidase method was used to detect the expression of endostatin, VEGF-C, and VEGFR-3 in 98 cases of NSCLC after radical surgery. Results: The positive expression rates of endostatin, VEGF-C, and VEGFR-3 were 30.6%, 79.6%, and 61.2%, respectively. Endostatin and VEGF-C expression has significant correlation ( P = 0.025 ), whereas VEGF-C and VEGFR-3 expression also had significant correlation ( P = 0.007 ). Endostatin and VEGF-C expression in patients with different number of lymph node metastasis and N staging were significantly different ( P < 0.05 ). VEGFR-3 expression was correlated with differentiation ( P = 0.013 ), whereas VEGF-C expression was correlated with vascular thrombosis ( P = 0.050 ). The positive expression rates of endostatin and VEGF-C were 88% in positive lymph nodes, compared with the rates in negative lymph nodes which were 32.7% and 57.1% ( P < 0.001 ). More micro-lymphatic vessels were observed in the metastatic lymph nodes than in non-metastatic nodes. Conclusion: The expressions of endostatin and VEGF-C are related to lymphatic metastasis. Endostatin could decrease VEGF-C expression to inhibit lymphatic metastasis, and VEGF-C/VEGFR-3 could increase MLVD to help lymphatic metastasis, which is helpful for NSCLC therapy. |
| |
| Keywords: | |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
